Introduction
============

COPD exacerbation requiring hospitalization is one of the most important causes of morbidity and mortality.[@b1-copd-13-2721] When acute respiratory failure occurs due to acute exacerbation of COPD (AECOPD), and intensive care unit (ICU) admission is needed, mortality risk is increased.[@b2-copd-13-2721]

The predominant reason for AECOPD is an infectious origin, and nearly half of these are bacterial infections.[@b3-copd-13-2721],[@b4-copd-13-2721] Airway inflammatory cells indicate the severity and etiology of AECOPD. When neutrophils predominate in the airways, the exacerbation tends to be severe, while airway eosinophilia at the time of exacerbation indicates a viral etiology.[@b3-copd-13-2721],[@b4-copd-13-2721] Recent studies showed a good correlation between sputum and peripheral blood eosinophil (PBE) count in patients with COPD. In addition, PBE ≥2% was shown to be a valuable indicator of corticosteroid response.[@b5-copd-13-2721]--[@b8-copd-13-2721]

There have been some useful recent treatment approaches using clinical and symptomatic findings. Respiratory symptoms, for example, dyspnea, cough, sputum, wheezing, and airway limitation (either increased resistance, ie, decreased FEV~1~ or decreased elastic recoil, ie, emphysema), may be useful in determining and treating AECOPD endotypes, namely neutrophilic and eosinophilic.[@b9-copd-13-2721] These AECOPD endotypes may lead to varying levels of increased inflammatory markers.

Recent studies have shown promising results with infectious inflammatory markers such as C-reactive protein (CRP), neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), platelet/mean platelet volume (PLT/MPV), and procalcitonin, and may represent useful tools for physicians managing AECOPD patients.[@b10-copd-13-2721]--[@b14-copd-13-2721]

The present study was conducted retrospectively in a 503-bedded, chest disease, teaching center hospital with previously diagnosed COPD patients admitted to the outpatients' clinic, ward, and ICU. We hypothesized that an early assessment of peripheral blood NLR and PBE percentage may be helpful for determining the severity of the AECOPD and the appropriate treatment approach.

Methods
=======

Study design
------------

A retrospective observational cross-sectional study was performed in the Health Science University Istanbul Sureyyapasa Chest Diseases and Thoracic Surgery Training and Research Hospital between January 2016 and December 2017. This study was approved by the local scientific committee of Hospital (date 08.11.2017/No:001). Ethical approval was in accordance with the Declaration of Helsinki. All data were collected retrospectively from the hospital database. Informed consent was not obtained from patients for the use of medical data for publication purposes since this was waived by the institution's local scientific committee, in line with the local legislation due to the retrospective nature of the study. All patients' ID information was strictly protected.

Patients
--------

A COPD diagnosis was previously made by a pulmonary specialist in our center if the patient was \>40 years, smoked \>10 packs/year or had been exposed to cigarette smoke. Patients with concurrent disease/s, for example, lung cancer, pneumonia, rheumatologic diseases with pulmonary involvement, interstitial lung diseases, asthma and rhinitis, chronic liver and renal diseases, and chronic neurological muscular diseases that may have contributed to these respiratory symptoms, or those with missing complete blood count (CBC) values, were excluded from the study.

Patients were divided according to endotypes, and further subdivided according to where they were admitted within the hospital as an indicator of exacerbation severity, that is, to the outpatient clinic, ward, or ICU. Patient enrollment is summarized in a flowchart in [Figure 1](#f1-copd-13-2721){ref-type="fig"}.

Definitions
-----------

### ICD codes

1.  J44.0--44.9: J44 Other COPD

2.  J44.0 COPD with acute lower respiratory infection

3.  J44.1 COPD with (acute) exacerbation

4.  J44.9 COPD, unspecified.

### COPD

Patients who had, an FEV~1~/FVC \<70% predicted, and had a history or physical evidence of dyspnea, cough, sputum, and wheezing.[@b1-copd-13-2721] Spirometry values were not recorded due to the absence of an electronic database.

### Neutrophilic COPD

If the percentage of PBEs was \<2%, it was accepted as neutrophilic COPD.

### Eosinophilic COPD

If the percentage of PBEs was ≥2%, it was accepted as eosinophilic COPD.[@b5-copd-13-2721]

### Acute exacerbation of COPD

It is an acute change in a patient's respiratory symptoms such as dyspnea, sputum production, volume and color change, and requires a change in current therapy.[@b1-copd-13-2721]

### Neutrophil to lymphocyte ratio

As a marker of systemic inflammation, NLR was defined as absolute neutrophil count divided by absolute lymphocyte count.

### Platelet to lymphocyte ratio

PLR was defined as the absolute platelet count divided by absolute lymphocyte count.[@b15-copd-13-2721]

### Platelets/MPV ratio

As a marker of systemic inflammation, the ratio of platelet count to MPV was calculated.

### Comorbidities

These were recorded from the patients' electronic data file and included diabetes mellitus, hypertension, congestive heart failure, coronary artery disease, arrhythmia, renal failure, anemia, and anxiety/depression.

### Study center protocol for ward and ICU admission, and outpatient clinic follow-up

In the study center, COPD patient hospitalization and outpatient follow-up were designed using the international/national COPD guidelines.[@b1-copd-13-2721],[@b16-copd-13-2721]

### Criteria for admission to the ward

Indication for hospital admission to the ward was according to the GOLD guidelines, that is, a marked increase in intensity of symptoms, severe underlying COPD, onset of new physical signs, failure of an exacerbation to respond to initial medical management, presence of serious comorbidities, frequent exacerbations, older age, and insufficient home support.[@b1-copd-13-2721]

### Criteria for admission to the ICU

The decision to admit the patient to the ICU was made according to the following GOLD guidelines: severe dyspnea that responds inadequately to initial emergency therapy, changes in mental status (confusion, lethargy, coma), persistent or worsening hypoxemia and/or severely worsening respiratory acidosis despite supplemental oxygen and noninvasive ventilation, the need for invasive mechanical ventilation, and/or hemodynamic instability.[@b1-copd-13-2721]

### Recorded data

Patient information recorded from the hospital database included age, gender, CBC and blood biochemistry values, laboratory results on admission at the hospital, and comorbidities. As inflammatory markers, total leukocyte count, neutrophil count, NLR, PLT/MPV, and CRP were recorded. Pulmonary function tests could not be obtained because of the absence of an electronic database of spirometry values. Nonetheless, the study authors checked all patients' findings if they appeared suspicious.

CBC counts including total leukocyte, neutrophil, eosinophil, lymphocyte, platelet counts, and MPV were determined using a Coulter LH 780 Hematology Analyzer (Beckman Coulter, Atlanta, GA, USA). CRP was determined using the nephelometry method BN II System (Siemens, Munich, Germany). The normal range of CRP is 0--5 mg/L.

Statistical analysis
--------------------

Statistical analysis was done using the portable SPSS-20 version package program. Patient demographics and all clinical data were summarized by descriptive analysis. The Student's *t*-test was used for continuous variables (ie, age, CBC values, biochemistry values, NLR, PLR, PLT/MPV, and CRP), if distributed normally in the two groups. The values from the Student's *t*-test were shown as the mean ± SD. If the groups were distributed nonnormally, the nonparametric Mann--Whitney *U* test was used, and the values were shown as the median and interquartile range. Dichotomous values (gender and presence of comorbid diseases) were compared using the chi-squared test. If n\<5, the Fisher's exact test was used and values were shown as count and percentage. The Kruskal--Wallis nonparametric test was used for comparison of inflammatory markers of COPD patients according to where they were admitted (outpatient clinic, ward, or ICU). To define the hospital mortality cutoff values of NLR, PLR, PLT/MPV, and CPR, the receiver operating characteristic (ROC) curve was used, and the area under the curve (AUC) was obtained to determine the optimal cutoff values. If the *P*-value was \<0.05, it was accepted as statistically significant.

Results
=======

In the study period, hospital electronic database revealed within the J 44.0--J 44.9 International coding system 43,315 patients were admitted to the hospital, either to the outpatient clinic, the ward, or the ICU. These "COPD" codes indicate an exacerbation or a comorbid disease. The study enrollment criteria resulted in 10,592 AECOPD patients being included in the study ([Figure 1](#f1-copd-13-2721){ref-type="fig"}). The patients with AECOPD stratification, that is, according to endotype, are summarized in [Figure 1](#f1-copd-13-2721){ref-type="fig"}. Both groups were subdivided according to where they were admitted to the hospital ([Figure 1](#f1-copd-13-2721){ref-type="fig"}). The majority of COPD patients were excluded from the study due to absence of CBC values on the day of hospitalization.

[Table 1](#t1-copd-13-2721){ref-type="table"} shows the comparison of neutrophilic and eosinophilic endotype groups relative to demographics, comorbidities, CBC, and biochemistry values, inflammatory markers at the time of admission to the hospital, place of admission to the hospital (outpatient clinic, ward, or ICU), and ward and ICU mortality. The CBC and biochemistry values from both groups were statistically, but not clinically, significant. The eosinophilic endotype was seen in nearly 38.3% of the included patients. In-hospital mortality was observed in 32 of the 2,728 hospitalized patients with AECOPD (16 of which were in the ICU).

[Table 2](#t2-copd-13-2721){ref-type="table"} shows the comparison of eosinophilic and neutrophilic AECOPD patients' inflammatory markers on admission to the outpatient clinic, the ward, or the ICU. Relative to disease severity, CRP, white blood cell count, NLR, and PLR were all significantly increased, and PLT/MPV was significantly decreased ([Table 2](#t2-copd-13-2721){ref-type="table"}).

[Table 3](#t3-copd-13-2721){ref-type="table"} shows a comparison of inflammatory markers relative to disease severity based on where the patient was admitted, and in both AECOPD endotypes CRP was significantly increased relative to attack severity. Neutrophilic AECOPD patients had statistically significant increased NLR values as the attack severity increased while NLR did not increase with attack severity in eosinophilic AECOPD patients.

The cutoff values for NLR, PLR, PLT/MPV, and CRP in hospital mortality were analyzed by the ROC and AUC and are summarized in [Figure 2](#f2-copd-13-2721){ref-type="fig"} and [Table 4](#t4-copd-13-2721){ref-type="table"}, respectively. Among the inflammatory markers, the highest AUC for hospital mortality was obtained with NLR.

[Table 4](#t4-copd-13-2721){ref-type="table"} shows inflammatory marker values relative to hospital mortality in patients with AECOPD compared by the area under the ROC curve analysis.

The cutoff values of NLR, CRP, PLR, and PLT/MPV for mortality are summarized in [Table 5](#t5-copd-13-2721){ref-type="table"}.

Discussion
==========

The present study showed that the inflammatory markers NLR, CRP, and PLR (but not PLT/MPV ratio) in patients with eosinophilic and neutrophilic endotypes of AECOPD increased significantly relative to disease severity. The increase in NLR was far more significant in neutrophilic AECOPD, compared with eosinophilic AECOPD. Relative to disease severity, the PLT/MPV ratio decreased in AECOPD patients. NLR and CRP were better predictors of hospital mortality than the other inflammatory markers.

Pathobiological mechanisms (endotypes) of exacerbation of COPD: eosinophilic and neutrophilic
---------------------------------------------------------------------------------------------

Since the last decade there have been many studies on the COPD endotypes with the aim of developing targeted and more effective therapeutic alternatives, or altering existing strategies. Recently, Agustí et al reviewed the implications of endotyping with respect to treatment in patients with COPD.[@b9-copd-13-2721] Clinical presentations of COPD or "phenotypes" result from the endotypes that indicate the pathobiological mechanisms, which are effected by exposome, that is, cumulative exposure of cigarette smoking, air pollution, infections, foods and allergens, and related to genome.[@b9-copd-13-2721],[@b17-copd-13-2721] In the present study, we investigated the biomarkers NLR, PLR, PLT/MPV, and CRP in patients with a clinical presentation of AECOPD with varying severity and different underlying endotypes. Our results, as well as current knowledge, point to the use of different biomarkers in the different endotypes to assess treatment response in the follow-up period.

In the present study, the presence of the eosinophilic endotype was found to be higher in the mild-to-moderate AECOPD group. Previous studies have also found that the PBE count is decreased relative to the exacerbation severity.[@b18-copd-13-2721]--[@b22-copd-13-2721] One may assume that patients with the eosinophilic endotype may have a good response to a treatment approach such as steroids. However, Vedel-Krogh et al recently published a study on patients with COPD exacerbations and revealed that those COPD patients with blood eosinophils \>0.34×10^9^ cells/L were found to be at increased risk of either moderate or severe AECOPD.[@b23-copd-13-2721] They showed the eosinophilic endotype to be associated with increased exacerbation. Some recent studies have shown a good response to steroid treatment in AECOPD patients with a predominance of PBEs.[@b5-copd-13-2721],[@b7-copd-13-2721],[@b24-copd-13-2721],[@b25-copd-13-2721] In previous studies neutrophilic AECOPD was defined as having an NLR \>3.54, and this was an indicator for considering antibiotic treatment.[@b18-copd-13-2721] We demonstrated that NLR values in neutrophilic group increased gradually relative to where the patient was admitted, that is, outpatient, ward, and ICU. However, NLR values in the eosinophilic group were at similarly low levels regardless of where the patient was admitted ([Figure 2](#f2-copd-13-2721){ref-type="fig"}).

CRP showed a similar increase with increased severity in both endotypes of AECOPD indicating a direct association of CRP and the severity of COPD exacerbation. While NLR values increased with severity in the neutrophilic group, we found no significant change in NLR with the severity of COPD exacerbation in the eosinophilic endotype, and in fact the NLR values in the eosinophilic endotype were within the normal range for NLR (normal NLR =1.65 range 0.78--3.53).[@b26-copd-13-2721] Thus, in the case of AECOPD where the CRP levels increase with an increased severity of exacerbation, and the NLR is nearly normal or slightly elevated, it may be helpful to assess viral etiology before initiating antibiotic or steroid treatment. These results suggest using both CRP and NLR levels to predict severity and to determine the management of AECOPD.

Bafadhel et al defined four endotypes of AECOPD (with biomarkers) as follows: bacterial (sputum interleukin beta 1), viral (serum CXCL10), eosinophilic (blood eosinophil), and pauciinflammatory.[@b5-copd-13-2721],[@b27-copd-13-2721] Brightling proposed that we need a deeper understanding of the COPD phenotypes right from their genetic origin (ie, endotypes) through to the resultant phenotypes.[@b10-copd-13-2721] Agustí et al recommended the treatment of COPD in four groups to be focused only on the pulmonary component and based on endotypes, that is, airway remodeling, neutrophilic, eosinophilic, and decrease apoptosis-increase repair presence of biomarkers and precision treatments respectively.[@b9-copd-13-2721] The present study highlights the need for future molecular studies to investigate effector genes and treatment modalities of AECOPD ([Figure 3](#f3-copd-13-2721){ref-type="fig"}).

A single study from the last two decades reported that CRP levels \>8 mg/mL, together with Anthonisen et al's criteria,[@b28-copd-13-2721] support the objective diagnosis of AECOPD.[@b29-copd-13-2721] In the present study, CRP values in the outpatient clinic, ward, and ICU for patients with AECOPD increased relevant to severity. Günay et al showed that NLR values increased significantly in AECOPD (NLR =4.28) compared with stable COPD patients (NLR =2.59), and NLR values in COPD patients were significantly higher than healthy controls (NLR =1.71).[@b11-copd-13-2721] Lee et al also studied NLR in patients with COPD. They found significantly higher levels of NLR in stable COPD patients compared with healthy controls, and if the level of NLR was \>2.8, the risk of hospitalization increased.[@b30-copd-13-2721] As the clinical deterioration proceeded in our study, the inflammatory markers, CRP, NLR, and PLR, were increased and PLT/MPV was decreased in both the eosinophilic and the neutrophilic endotypes. Yao et al found that higher levels of NLR (\>6.24), CRP (\>16.45 g/dL), and PLR (\>182.68) increased the risk of hospital mortality in AECOPD.[@b15-copd-13-2721] In the present study, NLR, CRP, and PLT/MPV showed significant values of ROC AUC for hospital mortality in hospitalized patients with AECOPD; however, PLR did not ([Figure 2](#f2-copd-13-2721){ref-type="fig"}). The cutoff values of mortality of patients with AECOPD in the ward and ICU were higher than Yao's results.

Limitations
-----------

There are some limitations to this study. Firstly, it was of retrospective nature. All included patients were obtained using an electronic system after entering data selection rules which included having CBC values on the day of admission to the hospital and a diagnosis of AECOPD. Many potential study subjects were missed because their CBC values were on the day before or after admission to the hospital. Nonetheless, as the study values were obtained electronically using the hospital database, incorrect data entry was prevented. Secondly, the study was undertaken on a single disease (COPD) and our results cannot be generalized to all diseases. However, these study results involve a large number of COPD patients, are valuable, and worth considering for this specific disease. Thirdly, although the diagnosis of COPD was based on spirometry values, we were unable to show these values due to the fact that they were not electronically available in the system. Nonetheless, the study was conducted in a tertiary teaching hospital for chest diseases which is the biggest hospital in our country (503 beds for chest diseases only) and the diagnosis was made by a pulmonary specialist (under control and with other academic pulmonary specialists), with very little suspicion of misdiagnosis of COPD.

Conclusion
==========

Despite technological advances and new biomarkers, there is still a current practice of looking only at leukocytes in CBC values as markers of infection. This study shows that NLR and PLR, calculated from CBC parameters, can be used to predict the severity of exacerbation of COPD. Similarly, NLR values in combination with physical findings may be useful when deciding where to admit the patient. If COPD patients with exacerbation have an NLR of 3.5--4.0, then the patient may be deemed suitable for outpatient follow-up without hospitalization. If the NLR is 6.5--7.0, we recommend hospitalization to the ward, and if the NLR is 13.0--14, admission to the ICU should be considered. We also recommend calculating the NLR and PLR values automatically and have these included in the CBC output, thus facilitating easier decision-making for the physicians in the outpatient clinics and emergency departments.

The present study findings may provide crucial information for defined exacerbation endotypes, the severity of exacerbation, and treatment response during follow-up with cheap, easy, and quick to obtain inflammatory markers. PBEs percentage, NLR and PLR may be used as biomarkers of AECOPD and may become important in medical decisions following future studies. These results may thus play a key role in clinical practice to prevent hospitalization and decrease the length of hospital stay and mortality in patients with AECOPD.
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![Flowchart of patient data.\
**Abbreviations:** CBC, complete blood count; ICU, intensive care unit.](copd-13-2721Fig1){#f1-copd-13-2721}

![ROC curves of inflammatory markers for mortality of hospitalized COPD acute exacerbation patients.\
**Note:** Diagonal segments are produced by ties.\
**Abbreviations:** ROC, receiver operating characteristic; PLR, platelet to lymphocyte ratio; PLT/MPV, platelet/mean platelet volume; CRP, C-reactive protein; NLR, neutrophil to lymphocyte ratio.](copd-13-2721Fig2){#f2-copd-13-2721}

![A treatment approach for chronic obstructive pulmonary diseases with respect to endotypes.\
**Abbreviations:** PBE, peripheral blood eosinophil; NLR, neutrophil to lymphocyte ratio.](copd-13-2721Fig3){#f3-copd-13-2721}

###### 

Baseline characteristics of neutrophilic and eosinophilic acute exacerbation of COPD

                                                                                              Neutrophilic COPD N=6,537   Eosinophilic COPD N=4,056   *P*-value
  ------------------------------------------------------------------------------------------- --------------------------- --------------------------- -----------
  Age, median (IQR) years[a](#tfn1-copd-13-2721){ref-type="table-fn"}                         69 (61--77)                 67 (59--75)                 \<0.001
  Male, n (%)                                                                                 4,325 (66)                  2,931 (72)                  \<0.001
  **CBC, median (IQR) values[a](#tfn1-copd-13-2721){ref-type="table-fn"}**                                                                            
  Leucocyte count, 10^9^ L                                                                    9.90 (7.80--12.80)          8.30 (6.90--9.99)           \<0.001
  Neutrophil count                                                                            7.90 (5.40--10.20)          5.10 (4.00--6.59)           \<0.001
  Lymphocyte count                                                                            1.50 (0.95--2.10)           1.91 (1.50--2.50)           \<0.001
  Monocyte count                                                                              0.60 (0.48--0.90)           0.62 (0.50--0.80)           0.036
  Erythrocyte count, 10^12^ L                                                                 4.64 (4.18--5.07)           4.76 (4.36--5.15)           \<0.001
  Hemoglobin, g/dL                                                                            13.0 (11.0--14.0)           14.0 (12.0--15.0)           \<0.001
  Hematocrit, %                                                                               40 (36--44)                 41 (36--44)                 0.25
  MCV, fL                                                                                     86.6 (82.5--90.4)           86.8 (82.9--90.3)           0.25
  Platelet count, 10^9^ L                                                                     256 (206--320)              252 (209--307)              0.08
  Mean platelet volume                                                                        8 (8--9)                    8 (8--9)                    0.64
  **Biochemistry, median (IQR) values[a](#tfn1-copd-13-2721){ref-type="table-fn"}**                                                                   
  Blood glucose, mg/dL                                                                        132 (106--176)              112 (95--142)               \<0.001
  BUN, mg/dL                                                                                  44 (33--62)                 38 (30--51)                 \<0.001
  Serum creatinine, mg/dL                                                                     0.78 (0.61--1.01)           0.80 (0.62--1.01)           0.92
  AST, U/L                                                                                    22 (17--33)                 22 (17--29)                 0.005
  ALT, U/L                                                                                    18 (12--29)                 16 (12--24)                 \<0.001
  Albumin, g/dL                                                                               3.6 (3.2--3.9)              3.7 (3.3--4.0)              \<0.001
  Sodium, mmol/L                                                                              138 (135--140)              138 (136--140)              \<0.001
  Potassium, mmol/L                                                                           4.4 (4.0--4.8)              4.4 (4.1--4.7)              0.049
  **Inflammatory markers, median (IQR) values[a](#tfn1-copd-13-2721){ref-type="table-fn"}**                                                           
  Neutrophil to lymphocyte ratio                                                              5.11 (2.92--9.64)           2.62 (1.88--3.80)           \<0.001
  Platelet to lymphocyte ratio                                                                175.66 (118.46--281.11)     130.00 (98.66--175.38)      \<0.001
  Platelet to MPV ratio                                                                       31 (24--40)                 30 (24--39)                 0.18
  CRP, mg/dL                                                                                  11.6 (4.0--36.4)            7.7 (3.4--21.2)             \<0.001
  **Admission to the hospital, n (%)**                                                                                                                
  Outpatient clinic                                                                           4,367 (67)                  3,497 (86)                  \<0.001
  Ward                                                                                        1,823 (28)                  410 (10)                    
  ICU                                                                                         346 (5)                     149 (4)                     
  **Mortality, n (%)**                                                                        29 (0.4)                    3 (0.1)                     0.001

**Note:**

Median (25%--75%), Mann--Whitney *U* test.

**Abbreviations:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CBC, complete blood count; CRP, C-reactive protein; ICU, intensive care unit; IQR, interquartile range; MCV, mean corpuscular volume; MPV, mean platelet volume.

###### 

Comparison of inflammatory markers in neutrophilic and eosinophilic COPD exacerbation

                                                         Neutrophilic (PBE \< 2%) N=6,537   Eosinophilic (PBE ≥2%) N=4,056   *P*-value                             
  ------------------------------------------------------ ---------------------------------- -------------------------------- ----------- ------------------------- -------------
  **Outpatient clinic**                                                                                                                                            
  Patients[a](#tfn3-copd-13-2721){ref-type="table-fn"}   4,367                              --                               3,497       --                        
  WBC (10^9^ L)                                          4,367                              9.70 (7.76--12.50)               3,497       8.30 (6.90--9.93)         \<**0.001**
  NLR                                                    4,367                              4.21 (2.58--7.47)                3,497       2.50 (1.83--3.62)         \<**0.001**
  CRP (mg/dL)                                            1,276                              7.7 (3.4--22.7)                  1,445       5.7 (3.3--12.7)           \<**0.001**
  PLT/MPV ×10^3^                                         4,367                              32 (24--41)                      3,497       31 (24--39)               **0.004**
  PLR                                                    4,367                              155.53 (110.50--236.67)          3,497       126.54 (97.53--169.09)    \<**0.001**
  **Ward**                                                                                                                                                         
  Patients[a](#tfn3-copd-13-2721){ref-type="table-fn"}   1,823                              --                               410         --                        
  WBC (10^9^ L)                                          1,823                              10.20 (8.00--13.10)              410         8.20 (6.60--10.20)        \<**0.001**
  NLR                                                    1,823                              7.57 (4.29--13.20)               410         3.43 (2.44--4.92)         \<**0.001**
  CRP (mg/dL)                                            1,788                              14.0 (4.6--42.3)                 402         19.0 (8.4--41.7)          \<**0.001**
  PLT/MPV                                                1,823                              30 (23--40)                      410         29 (22--40)               0.49
  PLR                                                    1,823                              228.33 (145.38--366.67)          410         156.37 (114.21--216.67)   \<**0.001**
  **ICU**                                                                                                                                                          
  Patients[a](#tfn3-copd-13-2721){ref-type="table-fn"}   346                                --                               149         --                        
  WBC (10^9^ L)                                          346                                10.07 (7.70--13.40)              149         8.30 (7.00--9.81)         \<**0.001**
  NLR                                                    346                                8.60 (4.53--16.60)               149         3.42 (2.57--5.10)         \<**0.001**
  CRP (mg/dL)                                            337                                20.4 (8.6--67.6)                 147         25.1 (12.9--47.6)         0.90
  PLT/MPV                                                346                                28 (21--38)                      149         27 (20--35)               0.19
  PLR                                                    346                                246.88 (159.74--433.33)          149         143.85 (112.78--204.17)   \<**0.001**

**Note:**

Median and interquartile range (25th--75th percentile). Significant values are written bold.

**Abbreviations:** CRP, C-reactive protein; ICU, intensive care unit; NLR, neutrophil to lymphocyte ratio; PBE, peripheral blood eosinophilia; PLR, platelet to lymphocyte ratio; PLT/MPV, platelet to mean platelet volume; WBC, white blood cell count.

###### 

Comparison of inflammatory markers in AECOPD patients on the day of admission to the ICU, ward, or outpatients' clinic

                      ICU   Ward                      Outpatients' clinic   *P*-value[a](#tfn5-copd-13-2721){ref-type="table-fn"}                                     
  ------------------- ----- ------------------------- --------------------- ------------------------------------------------------- ------- ------------------------- ---------
  **Total patient**                                                                                                                                                   
  CRP (mg/dL)         484   22.8 (9.9--55.3)          2,190                 15.0 (5.2--42.2)                                        2,721   6.4 (3.4--16.8)           \<0.001
  NLR                 495   5.94 (3.40--12.87)        2,233                 6.33 (3.58--11.6)                                       7,864   3.20 (2.12--5.45)         \<0.001
  PLR                 495   207.39 (134.68--348.57)   2,233                 208.46 (136.39--337.78)                                 7,864   140.43 (103.64--202.35)   \<0.001
  PLT/MPV             495   27.9 (20.7--36.4)         2,233                 29.6 (22.5--39.6)                                       7,864   31.1 (24.3--40.1)         \<0.001
  **Neutrophilic**                                                                                                                                                    
  CRP (mg/dL)         337   20.4 (8.6--67.6)          1,788                 14.0 (4.6--42.3)                                        1,276   7.7 (3.4--22.7)           \<0.001
  NLR                 346   8.60 (4.53--16.60)        1,823                 7.57 (4.29--13.20)                                      4,367   4.21 (2.58--7.47)         \<0.001
  PLR                 346   246.88 (159.74--433.33)   1,823                 228.33 (145.38--366.67)                                 4,367   155.53 (110.50--236.67)   \<0.001
  PLT/MPV             346   28.2 (21.1--37.7)         1,823                 29.6 (22.5--39.6)                                       4,367   31.7 (24.2--40.9)         \<0.001
  **Eosinophilic**                                                                                                                                                    
  CRP (mg/dL)         147   25.1 (12.9--47.6)         402                   19.0 (8.4--41.7)                                        1,445   5.7 (3.3--12.7)           \<0.001
  NLR                 149   3.42 (2.57--5.10)         410                   3.43 (2.44--4.92)                                       3,497   2.50 (1.83--3.62)         0.82
  PLR                 149   143.85 (112.78--204.17)   410                   156.37 (114.21--216.67)                                 3,497   126.54 (97.53--169.09)    \<0.001
  PLT/MPV             149   26.9 (19.6--35.0)         410                   29.5 (22.2--39.9)                                       3,497   30.5 (24.3--39.0)         0.09

**Note:**

Kruskal Wallis Test.

**Abbreviations:** AECOPD, acute exacerbation of Chronic Obstructive Pulmonary Disease; CRP, C-reactive protein; ICU, intensive care unit; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; PLT/MPV, platelet to mean platelet volume.

###### 

Area under the curve of inflammatory markers in patients with AECOPD who died in the hospital

  Test result variable(s)            Area   Asymptotic 95% CI   *P*-values   
  ---------------------------------- ------ ------------------- ------------ ---------
  C-reactive protein                 0.81   0.74                0.89         \<0.001
  Neutrophil to lymphocyte ratio     0.78   0.69                0.87         \<0.001
  Platelet to lymphocyte ratio       0.53   0.41                0.66         0.54
  Platelet to mean platelet volume   0.35   0.24                0.46         0.006

**Abbreviation:** AECOPD, acute exacerbation of chronic obstructive pulmonary diseases.

###### 

The cutoff values of inflammatory markers in patients with AECOPD who died in the hospital

  Variables                          Cutoff   Sensitivity, %   Specificity, %
  ---------------------------------- -------- ---------------- ----------------
  C-reactive protein                 35.1     81               60
  Neutrophil to lymphocyte ratio     8.01     78               60
  Platelet to lymphocyte ratio       228.87   52               55
  Platelet to mean platelet volume   19.3     66               16

**Abbreviation:** AECOPD, acute exacerbation of chronic obstructive pulmonary diseases.
